Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spebrutinib + Methotrexate in Active Rheumatoid Arthritis
NCT01975610Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of spebrutinib in rheumatoid arthritis (RA), sponsored by Celgene Corporation. Started Oct 2013; status: completed.
02
Drugs
spebrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01975610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01975610.